Affordable Access

deepdyve-link
Publisher Website

Monitoring the Efficacy of Chloroquine-Primaquine Therapy for Uncomplicated Plasmodium vivax Malaria in the Main Transmission Hot Spot of Brazil

Authors
  • Ladeia-Andrade, Simone
  • Menezes, Maria José
  • de Sousa, Taís Nóbrega
  • Silvino, Ana Carolina R.
  • de Carvalho, Jaques F. Jr.
  • Salla, Laís C.
  • Nery, Odaílton A.
  • de Melo, Gladson N. P.
  • Corder, Rodrigo M.
  • Rodrigues, Priscila T.
  • Ferreira, Marcelo U.
Type
Published Article
Journal
Antimicrobial Agents and Chemotherapy
Publisher
American Society for Microbiology
Publication Date
Apr 25, 2019
Volume
63
Issue
5
Identifiers
DOI: 10.1128/AAC.01965-18
PMID: 30782991
PMCID: PMC6496112
Source
PubMed Central
Keywords
License
Unknown

Abstract

Emerging Plasmodium vivax resistance to chloroquine (CQ) may undermine malaria elimination efforts in South America. CQ-resistant P. vivax has been found in the major port city of Manaus but not in the main malaria hot spots across the Amazon Basin of Brazil, where CQ is routinely coadministered with primaquine (PQ) for radical cure of vivax malaria. Here we randomly assigned 204 uncomplicated vivax malaria patients from Juruá Valley, northwestern Brazil, to receive either sequential (arm 1) or concomitant (arm 2) CQ-PQ treatment. Because PQ may synergize the blood schizontocidal effect of CQ and mask low-level CQ resistance, we monitored CQ-only efficacy in arm 1 subjects, who had PQ administered only at the end of the 28-day follow-up. We found adequate clinical and parasitological responses in all subjects assigned to arm 2. However, 2.2% of arm 1 patients had microscopy-detected parasite recrudescences at day 28. When PCR-detected parasitemias at day 28 were considered, response rates decreased to 92.1% and 98.8% in arms 1 and 2, respectively. Therapeutic CQ levels were documented in 6 of 8 recurrences, consistent with true CQ resistance in vivo . In contrast, ex vivo assays provided no evidence of CQ resistance in 49 local P. vivax isolates analyzed. CQ-PQ coadministration was not found to potentiate the antirelapse efficacy of PQ over 180 days of surveillance; however, we suggest that larger studies are needed to examine whether and how CQ-PQ interactions, e.g., CQ-mediated inhibition of PQ metabolism, modulate radical cure efficacy in different P. vivax -infected populations. (This study has been registered at ClinicalTrials.gov under identifier NCT02691910.)

Report this publication

Statistics

Seen <100 times